2021 American Transplant Congress
Intravenous Immunoglobulin Protects Liver Allograft from Ischemia Reperfusion Injury in Human Liver Transplantation
Department of Surgery, Allegheny General Hospital, Pittsburgh, PA
*Purpose: Ischemia/reperfusion (I/R) injury following prolonged cold storage has a significant impact on early and late human liver transplantation (LTx) outcomes. Prevention of I/R injury…2021 American Transplant Congress
Outcomes of Kidney Transplant Recipients with Antibody-mediated Allograft Rejection: A Retrospective Study
*Purpose: The optimal regimen for treating acute and chronic antibody-mediated rejection (AMR) in kidney transplant recipients has yet to be established. The purpose of the…2021 American Transplant Congress
Treatment of Bk Virus With Intravenous Immunoglobulin in Pediatric Kidney Transplant
Pediatric Nephrology and Transplant Services, Children's Hospital of Michigan, Detroit, MI
*Purpose: To study the prevalence of BK viremia (BKV) and BK Virus Nephropathy (BKVN) utilizing plasma BK quantitative Polymerase Chain Reaction (qPCR) and report outcomes…2021 American Transplant Congress
Intravenous Immunoglobulin in Heart Transplant Recipients with Hypogammaglobulinemia and Infection
Houston Methodist Hospital, Houston, TX
*Purpose: Hypogammaglobulinemia (HGG) is a complication of solid organ transplantation which has been associated with increased risk of infections. HGG is commonly defined as a…2021 American Transplant Congress
Outcomes of IVIG Monotherapy for Donor-Specific Antibodies After Lung Transplantation
Vanderbilt University Medical Center, Nashville, TN
*Purpose: De novo donor-specific antibodies (DSA) are a risk factor for antibody mediated rejection (AMR) and poor clinical outcomes after lung transplant (LT). Intravenous immune…2020 American Transplant Congress
Posttransplant Prophylactic Therapy with IVIG/Plasmapheresis in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies
Hospital Geral de Fortaleza, Fortaleza, Brazil
*Purpose: Patients with high levels of preformed donor-specific antibodies (DSA) are often not considered for kidney transplantation (KT), despite negative CDC-crossmatch, mainly in regions where…2020 American Transplant Congress
Osmotic Nephropathy from a Non-Sucrose Based IVIG
Nephrology, Mayo Clinic, Phoenix, AZ
*Purpose: We present a case of acute renal failure and hyperkalemia due to osmotic nephropathy from a non-sucrose based IVIG infusion therapy.*Methods: A 67-year-old man…2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…2019 American Transplant Congress
Predictors of Response to Intravenous Immunoglobulin for Treatment of Polyoma Nephropathy
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: BK nephropathy is an important cause of allograft dysfunction or loss. IVIg is hypothesized to be effective by providing passive immunity to BK virus…2019 American Transplant Congress
Reduction of Circulating DSA: Does It Affect Histology?
*Purpose: De novo donor specific antibodies (dnDSA) are reported in 13-30% of kidney transplant recipients. dnDSA has been associated with antibody mediated rejection (AMR) and…
- 1
- 2
- 3
- …
- 5
- Next Page »